BriaCell Therapeutics Corp. Files 8-K
Ticker: BCTXZ · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1610820
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-event
Related Tickers: BCTX
TL;DR
BriaCell Therapeutics filed an 8-K on Feb 3, 2025, detailing material agreements and equity sales.
AI Summary
BriaCell Therapeutics Corp. announced on February 3, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events, with financial statements and exhibits included. This filing follows a name change from Ansell Capital Corp. on June 13, 2014.
Why It Matters
This 8-K filing indicates significant corporate activity for BriaCell Therapeutics, including definitive agreements and equity sales, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can lead to stock price volatility, especially those related to definitive agreements and equity sales.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- February 3, 2025 (date) — Date of earliest event reported
- June 13, 2014 (date) — Date of name change
FAQ
What type of material definitive agreement did BriaCell Therapeutics Corp. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on February 3, 2025.
What was BriaCell Therapeutics Corp. previously known as?
BriaCell Therapeutics Corp. was formerly known as Ansell Capital Corp.
When did the company change its name?
The company's name change from Ansell Capital Corp. to BriaCell Therapeutics Corp. occurred on June 13, 2014.
What is the SIC code for BriaCell Therapeutics Corp.?
The Standard Industrial Classification (SIC) code for BriaCell Therapeutics Corp. is 2834, which corresponds to Pharmaceutical Preparations.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 3, 2025.
Filing Stats: 1,111 words · 4 min read · ~4 pages · Grade level 10.8 · Accepted 2025-02-05 17:02:43
Key Financial Figures
- $4.00 — s of the Companyat an offering price of $4.00 per common share. The Offering closed
- $3.05 million — The Company received gross proceeds of $3.05 million in connection with the Offering, before
- $5.00 — greement, and have an exercise price of $5.00 per common share. The Placement Agent W
Filing Documents
- form8-k.htm (8-K) — 56KB
- ex4-1.htm (EX-4.1) — 140KB
- ex5-1.htm (EX-5.1) — 16KB
- ex10-1.htm (EX-10.1) — 529KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-2.htm (EX-99.2) — 14KB
- ex99-3.htm (EX-99.3) — 14KB
- ex5-1_001.jpg (GRAPHIC) — 9KB
- ex5-1_002.jpg (GRAPHIC) — 10KB
- ex5-1_003.jpg (GRAPHIC) — 9KB
- ex99-3_001.jpg (GRAPHIC) — 14KB
- 0001493152-25-005043.txt ( ) — 1222KB
- bctx-20250203.xsd (EX-101.SCH) — 4KB
- bctx-20250203_def.xml (EX-101.DEF) — 29KB
- bctx-20250203_lab.xml (EX-101.LAB) — 36KB
- bctx-20250203_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams February 5, 2025 William V. Williams President and Chief Executive Officer